MaxCyte (LON:MXCT) Shares Down 5% – Should You Sell?

by · The Cerbat Gem

Shares of MaxCyte, Inc. (LON:MXCT – Get Free Report) fell 5% on Friday . The stock traded as low as GBX 1.50 and last traded at GBX 1.52. 1,180,524 shares were traded during trading, an increase of 2,706% from the average session volume of 42,065 shares. The stock had previously closed at GBX 1.60.

MaxCyte Stock Down 5.0%

The business’s 50 day moving average price is GBX 1.59 and its 200-day moving average price is GBX 22.81. The company has a debt-to-equity ratio of 8.59, a quick ratio of 14.38 and a current ratio of 9.81. The firm has a market capitalization of £1.62 million, a PE ratio of -0.04 and a beta of 1.13.

About MaxCyte

(Get Free Report)

MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients. For over 20 years, MaxCyte has been perfecting the art of cell-engineering, venturing beyond today’s process to innovate tomorrow’s solutions.

See Also